Everything below concerns anti-doping category. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-27. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Because severe cystic acne has the potential to cause permanent scarring over a short period, restrictions on its more immediate availability have proved contentious. In New Zealand, isotretinoin can be prescribed by any doctor but subsidized only when prescribed by a vocationally-registered general practitioner, dermatologist or nurse practitioner.
=== Class III === Proteins containing multiple covalently attached heme groups with low redox potential are included in class III. The heme C groups, all bis-histidinyl coordinated, are structurally and functionally nonequivalent and present different redox potentials in the range 0 to −400 mV. Members of this class are e.g. cytochrome c7 (triheme), cytochrome c3 (tetraheme), and high-molecular-weight cytochrome c (Hmc), containing 16 heme groups with only 30-40 residues per heme group. The 3D structures of a number of cyt c3 proteins have been determined. The proteins consist of four or five α-helices and two β-sheets wrapped around a compact core of four non-parallel hemes, which present a relatively high degree of exposure to the solvent. The overall protein architecture, heme plane orientations and iron-iron distances are highly conserved. An example is the photosynthetic reaction centre of Rhodopseudomonas viridis that contains a tetraheme cytochrome c subunit.
=== Gene silencing === The PCSK9 antisense oligonucleotide increases expression of the LDLR and decreases circulating total cholesterol levels in mice. A locked nucleic acid reduced PCSK9 mRNA levels in mice. Initial clinical trials showed positive results of ALN-PCS, which acts by means of RNA interference. In 2021, scientists demonstrated that CRISPR gene editing can decrease blood levels of LDL cholesterol in vivo in Macaca fascicularis monkeys for months by 60% via knockdown of PCSK9 in the liver. In 2023, a clinical trial demonstrated that VERVE-101 gene therapy, which works via CRISPR gene editing, could reduce LDL cholesterol by as much as 55% in human volunteers with heterozygous familial hypercholesterolemia.
==== C-C bond cleavage ==== The gem-diol intermediate cleaves at the C2-C3 bond to form one molecule of glycerate-3-phosphate and a negatively charged carboxylate. Stereo specific protonation of C2 of this carbanion results in another molecule of glycerate-3-phosphate. This step is thought to be facilitated by Lys175 or potentially the carbamylated Lys210.
Sources: en.wikipedia.org
In the following years, it became the basis for the prosecutions of the opposition and the officers during the imposition of the totalitarian regime in the country. Between 23 and 31 January, Kimon Georgiev visited Moscow, where he met Joseph Stalin and Georgi Dimitrov for the first time. The main purpose of the visit was the conclusion, with Soviet mediation, of an alliance treaty between Bulgaria and Yugoslavia. Secret letters to the treaty envisaged the future creation of a federation, without specifying whether on an equal basis between the two countries, which Bulgaria insisted on, or by incorporating Bulgaria into Yugoslavia as a sixth republic, which was the Yugoslav position. The treaty was never concluded because of the opposition of the United Kingdom and the United States, who believed that Bulgaria could not act independently until a peace treaty was concluded. On 9 February 1945, Kimon Georgiev gave a report on the government's work to the First Congress of the Fatherland Front. Days after the first executions under the decision of the so-called People's Court, he deplored the "cases of self-destruction, arbitrariness and violence" that had been allowed to take place, claimed that they had been curbed quickly, and expressed satisfaction at their being channeled through the People's Court. He states that the constitution and "the rights and liberties of the Bulgarian people" have been restored, although the Council of Ministers rules by ordinance-laws and political organizations outside the Fatherland Front have not been legalized.
Yariv phenylglycosides were concluded to be specific binding reagents for β-1,3-galactan chains longer than five residues. Seven residues and longer are sufficient for cross-linking, leading to precipitation of the glycans with the Yariv phenylglycosides, which are observed with classical AGPs binding to β-Yariv dyes. The same results were observed where in AGPs appear to need at least 5–7 β-1,3-linked Gal units to make aggregates with the Yariv reagent.
=== Fluorochemical manufacturing workers === People who work at fluorochemical production plants and in manufacturing industries that use PFAS in the industrial process can be exposed to PFAS in the workplace. Much of what we know about PFAS exposure and health effects began with medical surveillance studies of workers exposed to PFAS at fluorochemical production facilities. These studies began in the 1940s and were conducted primarily at U.S. and European manufacturing sites. Between the 1940s and 2000s, thousands of workers exposed to PFAS participated in research studies that advanced scientific understanding of exposure pathways, toxicokinetic properties, and adverse health effects associated with exposure. The first research study to report elevated organic fluorine levels in the blood of fluorochemical workers was published in 1980. It established inhalation as a potential route of occupational PFAS exposure by reporting measurable levels of organic fluorine in air samples at the facility. Workers at fluorochemical production facilities have higher levels of PFOA and PFOS in their blood than the general population. Serum PFOA levels in fluorochemical workers are generally below 20,000 ng/mL but have been reported as high as 100,000 ng/mL, whereas the mean PFOA concentration among non-occupationally exposed cohorts in the same time frame was 4.9 ng/mL. Among fluorochemical workers, those with direct contact with PFAS have higher PFAS concentrations in their blood than those with intermittent contact or no direct PFAS contact.
Sources: en.wikipedia.org
== Other Branded Generics == Biqi is the brand name for its generic OTC anti-diarrhea pharmaceutical. The Company obtained approval to manufacture and sell Biqi in November 1999. Zaiqi is the brand name for the company's azithromycin granules antibiotics for the treatment of infections. Zaike is the brand name for its cefaclor in dry suspension antibiotics for the treatment of infections. Simcere Kechuanning is the brand name for Simcere Pharmaceutical's OTC herbal medicine used for the treatment of coughs. It comes in oral liquid and tablet formulations. Zaikang is the brand name for its OTC compound zinc gluconate and ibuprofen granules for the treatment of cold symptoms, such as fever, nasal congestion, running nose and sneezing. Faneng is the brand name for the company's alfacalcidol soft capsules for the treatment of osteoporosis.
At the hearing, he said that he "found Judge Jackson to be smart, well-versed in the law, and extraordinarily deft and artful in her ability to speak at length without saying anything of substance on critical questions—especially the limits of judicial power and the importance of judicial restraint", adding, "I don't agree with the judge on where, based on her opinions, she draws the limits of judicial power, and I don't think she places as great an importance as I do on judicial restraint in a Madisonian system of checks and balances and separation of powers, and, for that reason, I will be voting no." On July 27, 2022, Kennedy voted against the Chips and Science Act, a bill regarding semiconductor production. He called the bill "a subsidy to Big Tech", adding, "These are extraordinary American companies that Congress just helped, but they're very profitable, and the supply of chips is growing now. My concern is the amount of money. For that amount, we could have doubled the R&D tax credit for every company in America." On August 7, 2022, Kennedy voted against the Inflation Reduction Act, calling it a "massive tax-and-spending bill". While the bill was being amended, Kennedy attempted to include an amendment he drafted with Senator Raphael Warnock to cap the price of insulin at $35 per month; the amendment did not receive the 60 votes needed to be included.
However, only Lockyer proposed that the line was due to a new element, which he named after the Sun. The formal discovery of the element was made in 1895 by chemists Sir William Ramsay, Per Teodor Cleve, and Nils Abraham Langlet, who found helium emanating from the uranium ore cleveite, which is no longer regarded as a separate mineral species, but as a variety of uraninite. In 1903, large reserves of helium were found in natural gas fields in parts of the United States, by far the largest supplier of the gas. Liquid helium is used in cryogenics (its largest single use, consuming about a quarter of production), and in the cooling of superconducting magnets, with its main commercial application in MRI scanners. Helium's other industrial uses—as a pressurizing and purge gas, as a protective atmosphere for arc welding, and in processes such as growing crystals to make silicon wafers—account for half of the gas produced. A small but well-known use is as a lifting gas in balloons and airships. As with any gas whose density differs from that of air, inhaling a small volume of helium temporarily changes the timbre and quality of the human voice. In scientific research, the behavior of the two fluid phases of helium-4 (helium I and helium II) is important to researchers studying quantum mechanics (in particular the property of superfluidity) and to those looking at the phenomena, such as superconductivity, produced in matter near absolute zero. On Earth, it is relatively rare—5.2 ppm by volume in the atmosphere.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.